pI: 9.5718 |
Length (AA): 357 |
MW (Da): 41578 |
Paralog Number:
0
Signal peptide: Y | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 6 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
102 | 354 | 1sw0 (A) | 3 | 246 | 31.00 | 0 | 1 | 1.31 | -2.32 |
102 | 356 | 1b9b (A) | 2 | 251 | 28.00 | 0 | 1 | 1.16 | -2.24 |
95 | 354 | 2y6z (A) | 16 | 263 | 27.00 | 0 | 1 | 1.13989 | -0.97 |
103 | 353 | 1ney (A) | 3 | 245 | 28.00 | 0 | 1 | 1.15868 | -1.11 |
105 | 357 | 1m6j (A) | 6 | 259 | 30.00 | 0 | 1 | 1.23628 | -1.53 |
151 | 235 | 2h6r (A) | 45 | 120 | 38.00 | 0.26 | 0.94 | 0.568995 | -0.04 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
NA% percentile | intra-erythrocytic - 16 hs, intra-erythrocytic - 32 hs. | Otto TD |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | intra-erythrocytic - 8 hs, intra-erythrocytic - 40 hs, intra-erythrocytic - 48 hs, Ring. | Otto TD Zanghi G |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 0-20% percentile | intra-erythrocytic - 0 hs, intra-erythrocytic - 24 hs, Oocyst, Sporozoite, Female Gametocyte, Male Gametocyte. | Otto TD Zanghi G Lasonder E |
Lasonder E | Integrated transcriptomic and proteomic analyses of P. falciparum gametocytes. Molecular insight into sex-specific processes and translational repression. |
Otto TD | New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq. |
Zanghi G | A Specific PfEMP1 Is Expressed in P. falciparum Sporozoites and Plays a Role in Hepatocyte Infection. |
Ortholog group members (OG5_162077)
Species | Accession | Gene Product |
---|---|---|
Plasmodium berghei | PBANKA_0806500 | triosephosphate isomerase, putative |
Plasmodium falciparum | PF3D7_0318800 | triosephosphate isomerase, putative |
Plasmodium knowlesi | PKNH_0822700 | triosephosphate isomerase, putative |
Plasmodium vivax | PVX_095295 | triosephosphate isomerase, putative |
Plasmodium yoelii | PY00756 | triosephosphate isomerase, putative |
Theileria parva | TP04_0676 | triosephophate isomerase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
PBANKA_0806500 | Plasmodium berghei | Dispensable | plasmo |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Oryctolagus cuniculus | Triosephosphate isomerase | 248 aa | 31.2% | 247 aa | Compounds | References |
Leishmania major | triosephosphate isomerase | 251 aa | 31.1% | 251 aa | Compounds | References |
Trypanosoma cruzi | triosephosphate isomerase, putative | 251 aa | 29.9% | 251 aa | Compounds | References |
Target | Type | Source | Notes |
---|---|---|---|
PF3D7_0318800 | purified protein | BRENDA | A protein with this EC number or name or sequence has been purified from Plasmodium falciparum ( 3 ) |
19 literature references were collected for this gene.